Retrospective Evaluation of Commercial Spacers in Prostate Cancer Patients
NCT ID: NCT05354427
Last Updated: 2025-09-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
175 participants
OBSERVATIONAL
2020-06-18
2022-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rectal Spacers in Prostate Cancer Patients Undergoing Radiation Therapy
NCT06599476
An Observational Study of Radiotherapy After Injection of SpaceOAR Hydrogel
NCT05735652
Rectal Spacers Use in Prostate Cancer Radiation Therapy
NCT06594887
SpaceIT Hydrogel System for Perirectal Spacing
NCT06451614
Radiotherapy vs Observation for CRPC
NCT01590498
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Observation
Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with implantabale spacers.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients have been histologically diagnosed with invasive adenocarcinoma that is extracapsular with posterior extension
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BioProtect
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Maria Skłodowska, Curie (MCMCC)
Warsaw, , Poland
Cuf Porto institution
Porto, , Portugal
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLP-10095
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.